{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:44:40Z","timestamp":1787499880710,"version":"build-2736575974"},"reference-count":123,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008781","name":"Pomeranian Medical University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008781","id-type":"DOI","asserted-by":"crossref"}]},{"id":[{"id":"https:\/\/ror.org\/01v1rak05","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Vaptans are non-peptide arginine vasopressin (AVP) receptor antagonists essential for modulating water homeostasis. This review evaluates their chemical evolution from peptide analogs to orally bioavailable molecules and summarizes the pharmacokinetic profiles of key agents, including tolvaptan, conivaptan, and mozavaptan. Significant emphasis is placed on the clinical role of tolvaptan as a disease-modifying therapy in autosomal dominant polycystic kidney disease (ADPKD) and its efficacy in syndrome of inappropriate antidiuretic hormone secretion (SIADH). Furthermore, the impact of pharmacogenetic factors, especially CYP3A5 and SVEP1 polymorphisms, is explored as a potential source of inter-individual variability in treatment response. By integrating structural, metabolic, and genetic data, this article highlights the potential for personalized aquaretic therapy and identifies critical safety and monitoring protocols necessary for optimizing clinical outcomes.<\/jats:p>","DOI":"10.3390\/cells15151388","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:02:01Z","timestamp":1785510121000},"page":"1388","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Vaptans: A Narrative Review of Pharmacokinetics, Pharmacogenetics, and Clinical Applications"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7651-8741","authenticated-orcid":false,"given":"Martyna","family":"Lica-Miler","sequence":"first","affiliation":[{"name":"Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, Powsta\u0144c\u00f3w Wielkopolskich 72, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8320-0359","authenticated-orcid":false,"given":"Karol","family":"Miler","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Biochemistry, Pomeranian Medical University, Powsta\u0144c\u00f3w Wielkopolskich 72, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7025-3087","authenticated-orcid":false,"given":"Dorota","family":"Kostrzewa-Nowak","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Biochemistry, Pomeranian Medical University, Powsta\u0144c\u00f3w Wielkopolskich 72, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3804-440X","authenticated-orcid":false,"given":"Andrzej","family":"Ciechanowicz","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Biochemistry, Pomeranian Medical University, Powsta\u0144c\u00f3w Wielkopolskich 72, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Brodkiewicz","sequence":"additional","affiliation":[{"name":"Clinic of Pediatrics, Pediatric Nephrology, Dialysis and Treatment of Acute Poisoning, PUM Clinic in Szczecin at the \u201cZdroje\u201d Hospital, ul. Maczna 4, 70-780 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"R\u00f3\u017ca\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, Powsta\u0144c\u00f3w Wielkopolskich 72, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0801-7582","authenticated-orcid":false,"given":"Joanna","family":"St\u0119pniewska","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, Powsta\u0144c\u00f3w Wielkopolskich 72, 70-111 Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/ndt\/gfae235","article-title":"The Biology of Water Homeostasis","volume":"40","author":"Fenton","year":"2025","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"11663","DOI":"10.1073\/pnas.90.24.11663","article-title":"Cellular and Subcellular Immunolocalization of Vasopressin-Regulated Water Channel in Rat Kidney","volume":"90","author":"Nielsen","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/jme.0.0290001","article-title":"Vasopressin V2 Receptor Antagonists","volume":"29","author":"Verbalis","year":"2002","journal-title":"J. Mol. Endocrinol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10741-008-9108-8","article-title":"Pharmacology of Vasopressin Antagonists","volume":"14","author":"Boerrigter","year":"2009","journal-title":"Heart Fail. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Krisanapan, P., Tangpanithandee, S., Thongprayoon, C., Pattharanitima, P., Kleindienst, A., Miao, J., Craici, I.M., Mao, M.A., and Cheungpasitporn, W. (2023). Safety and Efficacy of Vaptans in the Treatment of Hyponatremia from Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH): A Systematic Review and Meta-Analysis. J. Clin. Med., 12.","DOI":"10.3390\/jcm12175483"},{"key":"ref_6","unstructured":"(2026, February 16). Samsca | European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/samsca."},{"key":"ref_7","unstructured":"(2026, February 16). Jinarc | European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/jinarc."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/apt.12025","article-title":"Meta-Analysis: The Safety and Efficacy of Vaptans (Tolvaptan, Satavaptan and Lixivaptan) in Cirrhosis with Ascites or Hyponatraemia","volume":"36","author":"Dahl","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Mise, A.D., Venneri, M., Ranieri, M., Centrone, M., Pellegrini, L., Tamma, G., and Valenti, G. (2019). Lixivaptan, a New Generation Diuretic, Counteracts Vasopressin-Induced Aquaporin-2 Trafficking and Function in Renal Collecting Duct Cells. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21010183"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/sj.ki.5000432","article-title":"Vasopressin Receptor Antagonists","volume":"69","author":"Greenberg","year":"2006","journal-title":"Kidney Int."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/toxsci\/kfae142","article-title":"Tolvaptan Safety in Autosomal-Dominant Polycystic Kidney Disease; a Focus on Idiosyncratic Drug-Induced Liver Injury Liabilities","volume":"203","author":"Hammond","year":"2025","journal-title":"Toxicol. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.kint.2023.02.010","article-title":"Drug Repurposing in Autosomal Dominant Polycystic Kidney Disease","volume":"103","author":"Zhou","year":"2023","journal-title":"Kidney Int."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s40620-021-01062-6","article-title":"Therapeutic Advances in ADPKD: The Future Awaits","volume":"35","author":"Capuano","year":"2022","journal-title":"J. Nephrol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"F1005","DOI":"10.1152\/ajprenal.00243.2011","article-title":"Tolvaptan Inhibits ERK-Dependent Cell Proliferation, Cl\u2212 Secretion, and in Vitro Cyst Growth of Human ADPKD Cells Stimulated by Vasopressin","volume":"301","author":"Reif","year":"2011","journal-title":"Am. J. Physiol.-Ren. Physiol."},{"key":"ref_15","first-page":"977","article-title":"Tolvaptan (Otsuka)","volume":"5","author":"Doggrell","year":"2004","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"F273","DOI":"10.1152\/ajprenal.00195.2005","article-title":"Vasopressin-2-Receptor Antagonism Augments Water Excretion without Changes in Renal Hemodynamics or Sodium and Potassium Excretion in Human Heart Failure","volume":"290","author":"Smith","year":"2006","journal-title":"Am. J. Physiol.-Ren. Physiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.2146\/ajhp120543","article-title":"Relative Bioavailability of Tolvaptan Administered via Nasogastric Tube and Tolvaptan Tablets Swallowed Intact","volume":"70","author":"McNeely","year":"2013","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0022-3565(24)37873-5","article-title":"OPC-41061, a Highly Potent Human Vasopressin V2-Receptor Antagonist: Pharmacological Profile and Aquaretic Effect by Single and Multiple Oral Dosing in Rats1","volume":"287","author":"Yamamura","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1177\/0091270007307877","article-title":"Pharmacokinetics, Pharmacodynamics, and Safety of Tolvaptan, a Nonpeptide AVP Antagonist, During Ascending Single-Dose Studies in Healthy Subjects","volume":"47","author":"Shoaf","year":"2007","journal-title":"J. Clin. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s00228-012-1295-5","article-title":"Pharmacokinetics and Pharmacodynamics of Single-Dose Oral Tolvaptan in Fasted and Non-Fasted States in Healthy Caucasian and Japanese Male Subjects","volume":"68","author":"Shoaf","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1365-2125.2011.04114.x","article-title":"Effects of CYP3A4 Inhibition and Induction on the Pharmacokinetics and Pharmacodynamics of Tolvaptan, a Non-Peptide AVP Antagonist in Healthy Subjects","volume":"73","author":"Shoaf","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1007\/s12272-014-0352-2","article-title":"Liquid Chromatography\u2013Tandem Mass Spectrometry Method for Determining Tolvaptan and Its Nine Metabolites in Rat Serum: Application to a Pharmacokinetic Study","volume":"37","author":"Furukawa","year":"2014","journal-title":"Arch. Pharm. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/toxsci\/kfv231","article-title":"Inhibition of Human Hepatic Bile Acid Transporters by Tolvaptan and Metabolites: Contributing Factors to Drug-Induced Liver Injury?","volume":"149","author":"Slizgi","year":"2016","journal-title":"Toxicol. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/cpt.2007","article-title":"Quantitative Systems Toxicology Modeling Predicts That Reduced Biliary Efflux Contributes to Tolvaptan Hepatotoxicity","volume":"109","author":"Beaudoin","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00228-011-1106-4","article-title":"Effect of Grapefruit Juice on the Pharmacokinetics of Tolvaptan, a Non-Peptide Arginine Vasopressin Antagonist, in Healthy Subjects","volume":"68","author":"Shoaf","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.3390\/jcm3041276","article-title":"Review of Tolvaptan\u2019s Pharmacokinetic and Pharmacodynamic Properties and Drug Interactions","volume":"3","author":"Bhatt","year":"2014","journal-title":"J. Clin. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"173157","DOI":"10.1016\/j.ejphar.2020.173157","article-title":"Revisit Ligand-Receptor Interaction at the Human Vasopressin V2 Receptor: A Kinetic Perspective","volume":"880","author":"Liu","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"9734","DOI":"10.1038\/s41467-025-64735-x","article-title":"Structural Insights into Antagonist Recognition by the Vasopressin V2 Receptor","volume":"16","author":"Zhang","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_29","unstructured":"(2026, July 29). Vaprisol (Conivaptan Hydrochloride Injection). U.S. Food and Drug Administration (FDA). Symlin (Pramlintide Acetate) Injection [Prescribing Information], Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2005\/021697lbl.pdf."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s002280050685","article-title":"Pharmacokinetic and Pharmacodynamic Effects of YM087, a Combined V1\/V2 Vasopressin Receptor Antagonist in Normal Subjects","volume":"55","author":"Burnier","year":"1999","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1210\/jc.2005-2287","article-title":"Efficacy and Safety of Oral Conivaptan: A V1A\/V2 Vasopressin Receptor Antagonist, Assessed in a Randomized, Placebo-Controlled Trial in Patients with Euvolemic or Hypervolemic Hyponatremia","volume":"91","author":"Ghali","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1527-3466.2007.00019.x","article-title":"Conivaptan: A Dual Receptor Vasopressin V1a\/V2 Antagonist","volume":"25","author":"Ali","year":"2007","journal-title":"Cardiovasc. Drug Rev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/j.1476-5381.1992.tb09058.x","article-title":"Characterization of a Novel Aquaretic Agent, OPC-31260, as an Orally Effective, Nonpeptide Vasopressin V2 Receptor Antagonist","volume":"105","author":"Yamamura","year":"1992","journal-title":"Br. J. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1172\/JCI116881","article-title":"Potent Aquaretic Agent. A Novel Nonpeptide Selective Vasopressin 2 Antagonist (OPC-31260) in Men","volume":"92","author":"Ohnishi","year":"1993","journal-title":"J. Clin. Investig."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.toxlet.2022.11.017","article-title":"Activation of Tolvaptan-Responsive T-Cell Clones with the Structurally-Related Mozavaptan","volume":"373","author":"Hammond","year":"2023","journal-title":"Toxicol. Lett."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.2215\/CJN.00160106","article-title":"Successful Long-Term Treatment of Hyponatremia in Syndrome of Inappropriate Antidiuretic Hormone Secretion with Satavaptan (SR121463B), an Orally Active Nonpeptide Vasopressin V2-Receptor Antagonist","volume":"1","author":"Soupart","year":"2006","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1172\/JCI119098","article-title":"Characterization of SR 121463A, a Highly Potent and Selective, Orally Active Vasopressin V2 Receptor Antagonist","volume":"98","author":"Gal","year":"1996","journal-title":"J. Clin. Investig."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1021\/jm980179c","article-title":"5-Fluoro-2-Methyl-N-[4-(5H-Pyrrolo [2,1-c]- [1,4]Benzodiazepin-10(11H)-Ylcarbonyl)-3- Chlorophenyl]Benzamide (VPA-985): An Orally Active Arginine Vasopressin Antagonist with Selectivity for V2 Receptors","volume":"41","author":"Albright","year":"1998","journal-title":"J. Med. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","article-title":"Autosomal Dominant Polycystic Kidney Disease","volume":"369","author":"Torres","year":"2007","journal-title":"Lancet"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(18)32782-X","article-title":"Autosomal Dominant Polycystic Kidney Disease","volume":"393","author":"Alam","year":"2019","journal-title":"Lancet"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1681\/ASN.2016090938","article-title":"Polycystic Kidney Disease without an Apparent Family History","volume":"28","author":"Iliuta","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1681\/ASN.2017050483","article-title":"Genetic Complexity of Autosomal Dominant Polycystic Kidney and Liver Diseases","volume":"29","author":"Torres","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1681\/ASN.2008050507","article-title":"Unified Criteria for Ultrasonographic Diagnosis of ADPKD","volume":"20","author":"Pei","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.kint.2024.07.010","article-title":"KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD): Executive Summary","volume":"107","author":"Torres","year":"2025","journal-title":"Kidney Int."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease","volume":"367","author":"Torres","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease","volume":"377","author":"Torres","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/ndt\/gfx043","article-title":"for the TEMPO 4:4 Trial Investigators. Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: The TEMPO 4:4 Trial","volume":"33","author":"Torres","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/nrm2278","article-title":"When Cilia Go Bad: Cilia Defects and Ciliopathies","volume":"8","author":"Fliegauf","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/ng1076","article-title":"Polycystins 1 and 2 Mediate Mechanosensation in the Primary Cilium of Kidney Cells","volume":"33","author":"Nauli","year":"2003","journal-title":"Nat. Genet."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.34067\/KID.0007342020","article-title":"Dose-Dependent Effect of Tolvaptan on Renal Prognosis in Patients with Autosomal Dominant Polycystic Kidney Disease","volume":"2","author":"Akihisa","year":"2021","journal-title":"Kidney360"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ekir.2024.01.020","article-title":"Prospective Study on Individualized Dose Adjustment of Tolvaptan Based on Urinary Osmolality in Patients With ADPKD","volume":"9","author":"Aguilera","year":"2024","journal-title":"Kidney Int. Rep."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.5414\/CNP104S14","article-title":"Real-World Evidence for Using Urine Osmolality as a Practical Tool in Tolvaptan Dose Optimization in Patients with ADPKD","volume":"104","author":"Hrovatin","year":"2025","journal-title":"Clin. Nephrol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.nefro.2022.10.002","article-title":"The Safety and Efficacy of Tolvaptan in the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease: A Systematic Review and Meta-Analysis","volume":"43","author":"Li","year":"2023","journal-title":"Nefrolog\u00eda"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.cld.2022.01.009","article-title":"Polycystic Kidney\/Liver Disease","volume":"26","author":"Roediger","year":"2022","journal-title":"Clin. Liver Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1093\/ndt\/gfac027","article-title":"Diagnosis and Risk Factors for Intracranial Aneurysms in Autosomal Polycystic Kidney Disease: A Cross-Sectional Study from the Genkyst Cohort","volume":"37","author":"Halimi","year":"2022","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/labinvest.2016.93","article-title":"Vasopressin Regulates the Growth of the Biliary Epithelium in Polycystic Liver Disease","volume":"96","author":"Mancinelli","year":"2016","journal-title":"Lab. Investig."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000477664","article-title":"Tolvaptan for the Treatment of Enlarged Polycystic Liver Disease","volume":"7","author":"Mizuno","year":"2017","journal-title":"Case Rep. Nephrol. Dial."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"32228","DOI":"10.1038\/s41598-025-15681-7","article-title":"The Effect of Tolvaptan on Renal Progression and Systemic Inflammation in ADPKD","volume":"15","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_59","first-page":"1","article-title":"Combinational Diuretics in HeartFailure","volume":"21","author":"Casado","year":"2024","journal-title":"Curr. Heart Fail. Rep."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Saepudin, S., Ball, P.A., and Morrissey, H. (2015). Hyponatremia during Hospitalization and In-Hospital Mortality in Patients Hospitalized from Heart Failure. BMC Cardiovasc. Disord., 15.","DOI":"10.1186\/s12872-015-0082-5"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/clc.22180","article-title":"Predictors of 30-Day Readmission in Patients Hospitalized With Decompensated Heart Failure","volume":"36","author":"Hernandez","year":"2013","journal-title":"Clin. Cardiol."},{"key":"ref_62","first-page":"e93460","article-title":"Revisiting the Role of Tolvaptan in the Management of Hyponatraemia in Acute Heart Failure: Balancing Quality of Life and Cost With Tolvaptan Treatment","volume":"17","author":"Olaogun","year":"2025","journal-title":"Cureus"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1002\/ehf2.14472","article-title":"Admission Hyponatraemia as Heart Failure Events Predictor in Patients with Acute Heart Failure","volume":"10","author":"Sarastri","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa065181","article-title":"Tolvaptan, a Selective Oral Vasopressin V2-Receptor Antagonist, for Hyponatremia","volume":"355","author":"Schrier","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart FailureThe EVEREST Outcome Trial","volume":"297","author":"Konstam","year":"2007","journal-title":"JAMA"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1053\/j.jvca.2016.06.013","article-title":"Efficacy of Tolvaptan on Fluid Management After Cardiovascular Surgery Using Cardiopulmonary Bypass","volume":"30","author":"Ito","year":"2016","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1053\/j.jvca.2018.12.001","article-title":"The Role of Tolvaptan Administration After Cardiac Surgery: A Meta-Analysis","volume":"33","author":"Bellos","year":"2019","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ijcard.2016.06.156","article-title":"Effects of Short-Term Administration of Tolvaptan after Open Heart Surgery","volume":"220","author":"Matsuyama","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Wang, W., Gao, F., He, X., Gao, Y., Shi, L., Liu, W., and Zhuang, X. (2023). Efficacy of Tolvaptan in Postoperative Volume Therapy for Acute Stanford Type A Aortic Dissection. BMC Cardiovasc. Disord., 23.","DOI":"10.1186\/s12872-023-03125-x"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s00595-020-01962-3","article-title":"Tolvaptan Can Limit Postoperative Paroxysmal Atrial Fibrillation Occurrence after Open-Heart Surgery","volume":"50","author":"Nakamura","year":"2020","journal-title":"Surg. Today"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"106973","DOI":"10.1016\/j.vph.2022.106973","article-title":"Tolvaptan Reduces Angiotensin II-Induced Experimental Abdominal Aortic Aneurysm and Dissection","volume":"144","author":"Wu","year":"2022","journal-title":"Vasc. Pharmacol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/eurjhf\/hfs051","article-title":"for the CK-LX2401 Study Investigators The Efficacy and Safety of Lixivaptan in Outpatients with Heart Failure and Volume Overload: Results of a Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study","volume":"14","author":"Ghali","year":"2012","journal-title":"Eur. J. Heart Fail."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1752-8062.2010.00217.x","article-title":"Rationale and Design of the Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III\/IV Cardiac Patient Evaluation (THE BALANCE) Study","volume":"3","author":"Abraham","year":"2010","journal-title":"Clin. Transl. Sci."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4103\/joacp.JOACP_263_17","article-title":"Efficacy of Vaptans for Correction of Postoperative Hyponatremia: A Comparison between Single Intravenous Bolus Conivaptan vs Oral Tolvaptan","volume":"34","author":"Rajan","year":"2018","journal-title":"J. Anaesthesiol. Clin. Pharmacol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1093\/ndt\/gfae162","article-title":"Hyponatraemia\u2014Treatment Standard 2024","volume":"39","author":"Spasovski","year":"2024","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.eprac.2025.04.012","article-title":"Low-Dose Tolvaptan for the Treatment of Syndrome of Inappropriate Antidiuretic Hormone\u2013Associated Hyponatremia: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis of Clinical Effectiveness and Safety","volume":"31","author":"Lewellyn","year":"2025","journal-title":"Endocr. Pract."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.eprac.2024.12.019","article-title":"Efficacy and Safety of Low-Dose Tolvaptan (7.5 Mg) in the Treatment of Inpatient Hyponatremia: A Retrospective Study","volume":"31","author":"Llewellyn","year":"2025","journal-title":"Endocr. Pract."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40261-016-0470-3","article-title":"The Efficacy and Safety of Tolvaptan in Patients with Hyponatremia: A Meta-Analysis of Randomized Controlled Trials","volume":"37","author":"Li","year":"2017","journal-title":"Clin. Drug Investig."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00467-023-06091-w","article-title":"Tolvaptan and Urea in Paediatric Hyponatraemia","volume":"39","author":"Veligratli","year":"2024","journal-title":"Pediatr. Nephrol."},{"key":"ref_80","unstructured":"(2026, February 16). Drugs@FDA: FDA-Approved Drugs, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=021697."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1159\/000106456","article-title":"Assessment of the Efficacy and Safety of Intravenous Conivaptan in Euvolemic and Hypervolemic Hyponatremia","volume":"27","author":"Zeltser","year":"2007","journal-title":"Am. J. Nephrol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/MAJ.0b013e31817b8148","article-title":"Efficacy and Safety of Oral Conivaptan, a Vasopressin-Receptor Antagonist, Evaluated in a Randomized, Controlled Trial in Patients With Euvolemic or Hypervolemic Hyponatremia","volume":"337","author":"Annane","year":"2009","journal-title":"Am. J. Med. Sci."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40261-020-00911-9","article-title":"Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage: A Safety and Tolerability Study","volume":"40","author":"Corry","year":"2020","journal-title":"Clin. Drug Investig."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s12028-010-9366-x","article-title":"A Bolus of Conivaptan Lowers Intracranial Pressure in a Patient with Hyponatremia after Traumatic Brain Injury","volume":"14","author":"Dhar","year":"2011","journal-title":"Neurocrit. Care"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Hedna, V.S., Bidari, S., Gubernick, D., Ansari, S., Satriotomo, I., Khan, A.A., and Qureshi, A.I. (2014). Treatment of Stroke Related Refractory Brain Edema Using Mixed Vasopressin Antagonism: A Case Report and Review of the Literature. BMC Neurol., 14.","DOI":"10.1186\/s12883-014-0213-0"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/ki.2012.274","article-title":"Oral Lixivaptan Effectively Increases Serum Sodium Concentrations in Outpatients with Euvolemic Hyponatremia","volume":"82","author":"Abraham","year":"2012","journal-title":"Kidney Int."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/ki.2012.275","article-title":"Lixivaptan Safely and Effectively Corrects Serum Sodium Concentrations in Hospitalized Patients with Euvolemic Hyponatremia","volume":"82","author":"Abraham","year":"2012","journal-title":"Kidney Int."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1517\/13543784.2011.579102","article-title":"The Potential Role for Lixivaptan in Heart Failure and in Hyponatremia","volume":"20","author":"Zmily","year":"2011","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Ectopic ADH Syndrome Therapeutic Research Group, Yamaguchi, K., Shijubo, N., Kodama, T., Mori, K., Sugiura, T., Kuriyama, T., Kawahara, M., Shinkai, T., and Iguchi, H. (2011). Clinical Implication of the Antidiuretic Hormone (ADH) Receptor Antagonist Mozavaptan Hydrochloride in Patients with Ectopic ADH Syndrome. jpn. J. Clin. Oncol., 41, 148\u2013152.","DOI":"10.1093\/jjco\/hyq170"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/eurjhf\/hfq226","article-title":"the DILIPO investigators Short- and Long-Term Treatment of Dilutional Hyponatraemia with Satavaptan, a Selective Arginine Vasopressin V2-Receptor Antagonist: The DILIPO Study","volume":"13","author":"Aronson","year":"2011","journal-title":"Eur. J. Heart Fail."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s00535-010-0240-6","article-title":"A Multicenter, Open-Label, Dose-Ranging Study to Exploratively Evaluate the Efficacy, Safety, and Dose\u2013Response of Tolvaptan in Patients with Decompensated Liver Cirrhosis","volume":"45","author":"Okita","year":"2010","journal-title":"J. Gastroenterol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1111\/hepr.13566","article-title":"Furosemide as a Factor to Deteriorate Therapeutic Efficacy of Tolvaptan in Patients with Decompensated Cirrhosis","volume":"50","author":"Uchida","year":"2020","journal-title":"Hepatol. Res."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Hosui, A., Tanimoto, T., Okahara, T., Ashida, M., Ohnishi, K., Wakahara, Y., Kusumoto, Y., Yamaguchi, T., Sueyoshi, Y., and Hirao, M. (2021). Early Administration of Tolvaptan Can Improve Survival in Patients with Cirrhotic Ascites. J. Clin. Med., 10.","DOI":"10.3390\/jcm10020294"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1681\/ASN.2009080857","article-title":"Oral Tolvaptan Is Safe and Effective in Chronic Hyponatremia","volume":"21","author":"Berl","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/j.1365-2036.2010.04236.x","article-title":"Clinical Trial: Short-Term Effects of Combination of Satavaptan, a Selective Vasopressin V2 Receptor Antagonist, and Diuretics on Ascites in Patients with Cirrhosis without Hyponatraemia\u2013a Randomized, Double-Blind, Placebo-Controlled Study","volume":"31","author":"Wong","year":"2010","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1053\/jhep.2002.36375","article-title":"Pharmacodynamic Effects of a Nonpeptide Antidiuretic Hormone V2 Antagonist in Cirrhotic Patients with Ascites","volume":"36","author":"Guyader","year":"2002","journal-title":"Hepatology"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s11011-013-9384-4","article-title":"Satavaptan Treatment for Ascites in Patients with Cirrhosis: A Meta-Analysis of Effect on Hepatic Encephalopathy Development","volume":"28","author":"Watson","year":"2013","journal-title":"Metab. Brain Dis."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.1111\/bcp.15367","article-title":"Vaptans for Oedematous and Hyponatraemic Disorders in Childhood: A Systematic Literature Review","volume":"88","author":"Piffer","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2215\/CJN.0000000000000022","article-title":"Tolvaptan for Children and Adolescents with Autosomal Dominant Polycystic Kidney Disease: Randomized Controlled Trial","volume":"18","author":"Mekahli","year":"2023","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00380-020-01743-5","article-title":"Efficacy and Safety of Tolvaptan after Pediatric Congenital Heart Disease Surgery","volume":"36","author":"Kojima","year":"2021","journal-title":"Heart Vessel."},{"key":"ref_101","first-page":"206","article-title":"Clinical Utility of Early Use of Tolvaptan in Very Elderly Patients with Acute Decompensated Heart Failure","volume":"18","author":"Niikura","year":"2017","journal-title":"Anatol. J. Cardiol."},{"key":"ref_102","first-page":"80","article-title":"Predictors of In-Hospital Mortality in Elderly Patients with Heart Failure Treated with Tolvaptan","volume":"9","author":"Kobayashi","year":"2023","journal-title":"Fujita Med. J."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"564","DOI":"10.31662\/jmaj.2024-0050","article-title":"Association of Early Tolvaptan Treatment and Length of In Hospital Stay in Elderly Patients with Acute Decompensated Heart Failure","volume":"7","author":"Suzuki","year":"2024","journal-title":"JMA J."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s40264-015-0327-3","article-title":"Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database","volume":"38","author":"Watkins","year":"2015","journal-title":"Drug Saf."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"12571","DOI":"10.1007\/s00210-025-04084-0","article-title":"Identification of Key Immune Genes of Drug-Induced Liver Injury Induced by Tolvaptan Based on Bioinformatics","volume":"398","author":"Yang","year":"2025","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.34067\/KID.0000000934","article-title":"Long-Term Experience of Tolvaptan: Is Hepatotoxicity Still a Concern?","volume":"6","author":"Brown","year":"2025","journal-title":"Kidney360"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1053\/j.ajkd.2022.08.012","article-title":"Clinical Pattern of Tolvaptan-Associated Liver Injury in Trial Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD): An Analysis of Pivotal Clinical Trials","volume":"81","author":"Alpers","year":"2023","journal-title":"Am. J. Kidney Dis."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1093\/ckj\/sfac076","article-title":"Evaluating the Impact of a Risk Evaluation and Mitigation Strategy with Tolvaptan to Monitor Liver Safety in Patients with Autosomal Dominant Polycystic Kidney Disease","volume":"15","author":"Estilo","year":"2022","journal-title":"Clin. Kidney J."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.xkme.2019.11.008","article-title":"Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients Treated With Tolvaptan","volume":"2","author":"Anderegg","year":"2020","journal-title":"Kidney Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/j.ekir.2019.09.002","article-title":"Role of Liver Transplantation in Tolvaptan-Associated Acute Liver Failure","volume":"4","author":"Endo","year":"2019","journal-title":"Kidney Int. Rep."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/HEP.0000000000001438","article-title":"Benefits and Challenges to Therapeutic Targeting of Bile Acid Circulation in Cholestatic Liver Disease","volume":"82","author":"Trauner","year":"2025","journal-title":"Hepatology"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.7150\/ijbs.69609","article-title":"Disruption of Peroxisome Proliferator-Activated Receptor \u03b1 in Hepatocytes Protects against Acetaminophen-Induced Liver Injury by Activating the IL-6\/STAT3 Pathway","volume":"18","author":"Zhang","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00003088-200038010-00003","article-title":"Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition","volume":"38","author":"Dresser","year":"2000","journal-title":"Clin. Pharmacokinet."},{"key":"ref_114","first-page":"391","article-title":"The Effect of Cytochrome P450 Metabolism on Drug Response, Interactions, and Adverse Effects","volume":"76","author":"Lynch","year":"2007","journal-title":"Am. Fam. Physician"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s40261-018-0714-5","article-title":"Impaired Renal Function May Not Negate the Efficacy of Tolvaptan in the Treatment of Cirrhotic Patients with Refractory Ascites","volume":"39","author":"Arase","year":"2019","journal-title":"Clin. Drug Investig."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Komiyama, Y., Kurosaki, M., Nakanishi, H., Takahashi, Y., Itakura, J., Yasui, Y., Tamaki, N., Takada, H., Higuchi, M., and Gotou, T. (2017). Prediction of Diuretic Response to Tolvaptan by a Simple, Readily Available Spot Urine Na\/K Ratio. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0174649"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1007\/s00535-015-1143-3","article-title":"Urinary Excretion of the Water Channel Aquaporin 2 Correlated with the Pharmacological Effect of Tolvaptan in Cirrhotic Patients with Ascites","volume":"51","author":"Nakanishi","year":"2016","journal-title":"J. Gastroenterol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1097\/MEG.0000000000001985","article-title":"Prediction factors of tolvaptan effectiveness in patients with refractory ascites complicated with hepatocellular carcinoma","volume":"33","author":"Imai","year":"2021","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1159\/000518099","article-title":"Plasma Renin Activity Predicts Prognosis and Liver Disease-Related Events in Liver Cirrhosis Patients with Ascites Treated by Tolvaptan","volume":"40","author":"Osawa","year":"2021","journal-title":"Dig. Dis."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00535-016-1233-x","article-title":"Predictive Factors of the Pharmacological Action of Tolvaptan in Patients with Liver Cirrhosis: A Post Hoc Analysis","volume":"52","author":"Sakaida","year":"2017","journal-title":"J. Gastroenterol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1159\/000509817","article-title":"Genetics May Predict Effectiveness of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease","volume":"51","author":"Sekine","year":"2020","journal-title":"Am. J. Nephrol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/bcpt.13355","article-title":"Impact of CYP3A5 Genotype on Tolvaptan Pharmacokinetics and Their Relationships with Endogenous Markers of CYP3A Activity and Serum Sodium Level in Heart Failure Patients","volume":"126","author":"Hoshikawa","year":"2020","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1111\/liv.15022","article-title":"A Genome-Wide Association Study Identifying SVEP1 Variant as a Predictor of Response to Tolvaptan for Cirrhotic Ascites","volume":"41","author":"Kawaratani","year":"2021","journal-title":"Liver Int."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/15\/1388\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T06:34:22Z","timestamp":1785738862000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/15\/1388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":123,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cells15151388"],"URL":"https:\/\/doi.org\/10.3390\/cells15151388","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]}}}